Lamivudine: Antiviral Therapy for HIV and Chronic Hepatitis B
Lamivudine is a potent nucleoside reverse transcriptase inhibitor (NRTI) with high antiviral activity. It is a fundamental component in the management of HIV-1 infection and chronic hepatitis B virus (HBV).
By mimicking natural DNA building blocks, Lamivudine inhibits the viral reverse transcriptase enzyme, effectively terminating the DNA chain and stopping the virus from replicating. This leads to a significant decrease in viral load and clinical improvement.
While used as a stand-alone treatment for HBV in some cases, it must always be used in combination with other antiretroviral agents for HIV to prevent the development of viral resistance.
Indications
- HIV-1 Infection: Treatment of HIV-infected adults and children as part of highly active antiretroviral therapy (HAART).
- Chronic Hepatitis B: Treatment of chronic HBV in patients with evidence of viral replication and active liver inflammation.
- Prevention of mother-to-child transmission and post-exposure prophylaxis.
Dosage and administration
The dosage depends on the indication and the patient's renal function. Available in 100 mg, 150 mg, and 300 mg tablets.
- For HIV: The standard adult dose is 300 mg daily, taken either as 150 mg twice daily or 300 mg once daily.
- For Hepatitis B: The standard adult dose is 100 mg orally once daily.
- Administration: Can be taken with or without food. Tablets should ideally be swallowed whole.
- Note: Dose adjustment is required for patients with impaired renal function (creatinine clearance < 50 mL/min).
- Hypersensitivity to Lamivudine or any of the inactive ingredients.
- Severe renal impairment (if appropriate dose reduction is not possible).
- Use in pregnancy (especially first trimester) should be carefully balanced against potential risks.
Lamivudine is generally well-tolerated. Potential side effects include:
- Common: Headache, malaise, fatigue, nausea, and diarrhea.
- Serious: Lactic acidosis and severe hepatomegaly with steatosis (rare but life-threatening).
- Warning: Abrupt discontinuation in patients with chronic HBV may lead to severe exacerbation of hepatitis. Liver function should be monitored closely for several months after stopping the drug.